A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · cited 3×
“…JAK 2 V617F mutation, haemoglobin concentration and/or Hct are currently used as a surrogate for RCM to distinguish between PV and essential thrombo-cythaemia (ET) (Arber et al , 2016), but Hct has the better accuracy in predicting RCM (Alvarez-Larr (cid:1) an et al , 2012; Ancochea et al , 2014).”
BackgroundMethodAge-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · cited 2×
“However, the JAK 2 V617F mutation has been identified in normal individuals, often at a low allele burden, with a frequency that increases with age (Gen-ovese et al , 2014; Jaiswal et al , 2014).”
BackgroundClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,276 · cited 2×
“…patients with exon 12 mutated-PV tend to be younger, with higher haemoglobin concentrations, lower white blood cell (WBC) and platelet counts, and an isolated increase in erythropoiesis without granulocytic or megakaryocytic morphological abnormalities (Scott et al , 2007; Passamonti et al , 2011).”
BackgroundSelf-citationEfficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., & Barbui, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035572 · Cited by 1,012
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409002 · Cited by 891 · cited 2×
“Following this, a phase III trial RESPONSE evaluated the efficacy and safety of ruxolitinib in a specific subgroup of PV patients who were both refractory to, or intolerant of, HC and who required ongoing phlebotomy and had splenomegaly (Vannucchi, 2015).”
MethodSelf-citationCardiovascular Events and Intensity of Treatment in Polycythemia Vera
Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., De Stefano, V., Elli, E., Iurlo, A., Latagliata, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208500 · Cited by 846 · cited 5×
“This target has now been validated in a randomised clinical trial by the Cytoreductive Therapy in PV (CYTO-PV) investigators who assessed the impact of stringent Hct reduction to 0 (cid:1) 45 compared with a more liberal target range of 0 (cid:1) 45 – 0 (cid:1) 50 (Marchioli et al , 2013).”
BackgroundMethodInfluentialHydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis
Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., & Barbui, T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321704 · Cited by 843 · cited 1×
“The efficacy of HC in controlling blood counts and preventing thrombosis has been extrapolated from the evidence in ET (Cortelazzo et al , 1995) and HC has been used in the management of PV.”
MethodVascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera
Marchioli, R., Finazzi, G., Landolfi, R., Kutti, J., Gisslinger, H., Patrono, C., Marilus, R., Villegas, A., Tognoni, G., & Barbui, T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.062 · Cited by 726 · cited 3×
“At diagnosis, in the largest prospective study to date, the European Collaboration on Low-Dose Aspirin in Poly-cythaemia Vera (ECLAP), age ≥ 65 years and a prior history of thrombosis were found to be the most important predictors of cardiovascular events (Marchioli et al , 2005).”
BackgroundTefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700 · cited 9×
“A long-term assessment from the ECLAP study showed no increased MDS/AML in those treated with HC alone (Finazzi et al , 2005) and a retrospective analysis showed no association between HC or busulfan and AML (Tefferi et al , 2013).”
BackgroundMethodInfluential
Metadata
- Authors
- McMullin, M. F., Harrison, C. N., Ali, S., Cargo, C., Chen, F., Ewing, J., Garg, M., Godfrey, A., S, S. K., McLornan, D. P., Nangalia, J., Sekhar, M., Wadelin, F., Mead, A. J., & the BSH Committee
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2018-11-27
- Volume
- 184
- Issue
- 2
- Pages
- 176-191
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2903319422
- Cited by
- 161
- References
- 70
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. https://app.cochat.ai/papers/10.1111/bjh.15648
- The paper
- McMullin, M. F., Harrison, C. N., Ali, S., Cargo, C., Chen, F., Ewing, J., Garg, M., Godfrey, A., S, S. K., McLornan, D. P., Nangalia, J., Sekhar, M., Wadelin, F., Mead, A. J., & the BSH Committee. (2019). A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. British Journal of Haematology. https://doi.org/10.1111/bjh.15648
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.